Jun 21, 2019 - The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
Jun 21, 2019 - We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Jun 19, 2019 - Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.
Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Jun 16, 2019 - Not all stocks are expensive. These drug stocks look like bargains.
Jun 04, 2019 - Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.
May 26, 2019 - There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.
May 23, 2019 - These three biotech stocks should turn out to be outstanding long-term growth vehicles.
May 20, 2019 - Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
May 19, 2019 - These drugs and the biotechs that make them could be on the way to tremendous success in the near future.